Our therapeutics pipeline includes anti-viral drug compounds such as QN-165 (formerly referred to as AS1411), cancer drug compounds such as QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device.
To learn more about partnering or licensing opportunities, please contact firstname.lastname@example.org
Select a drug candidate to learn more
|Program||Discovery||Preclinical||Phase 1||Phase 2|
QN-165 was studied in over 100 patients to treat AML and renal cell carcinoma in pre-Qualigen clinical trials.
QN-165 has potential to be broad based antiviral with COVID-19 as initial condition.